Latest Advanz Pharma News & Updates

See the latest news and media coverage for Advanz Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Advanz Pharma

Global specialty, hospital, and rare-disease pharmaceutical company

advanzpharma.com

Headquarters: London, United Kingdom
Company type: Public company
Number of employees: 730–1,000
Industry: Pharmaceuticals

Last updated September 23

Latest news about Advanz Pharma

In short: Advanz Pharma advanced its biosimilar portfolio via approvals and acquisitions while facing regulatory and legal setbacks in Europe.

Company announcements

January 30 Advanz Pharma

ADVANZ PHARMA announces patent settlement for Eylea biosimilar

Alvotech settles with Regeneron and Bayer, enabling marketing from January 2026 in UK and May 2026 in EEA and Switzerland.

December 18, 2025 Advanz Pharma

Advanz Pharma expands portfolio via acquisition

It acquires additional EMEA rights and global hospital medicine rights, strengthening global footprint and commitment to specialty medicines.

December 18, 2025 Advanz Pharma

Advanz Pharma acquires Progynova, Cyclo-Progynova in EMEA, Ilomedin globally

Progynova treats estrogen deficiency; Cyclo-Progynova regulates menstruation. Ilomedin addresses cardiovascular disorders including rare Thromboangiitis Obliterans. Deals expand specialty brands portfolio following prior Latin America and APAC acquisitions.

November 20, 2025 Advanz Pharma

Advanz Pharma announces EC approval for Gobivaz

The EC granted marketing authorizations for the biosimilar Gobivaz (golimumab) across the EEA for multiple indications and formats.

Media coverage

September 23 Sweet & Maxwell

General Court upholds revocation of marketing authorisation for chronic liver disease treatment - EU Law Live

The General Court dismissed an action brought by Advanz Pharma Ltd seeking annulment of the Commission’s decision to revoke the conditional marketing authorisation for Ocaliva...

March 16 Concurrences

The UK Competition Authority finds a pharmaceutical company guilty of excessive and unfair pricing for Liothyronine Tablets and imposes £101M fine (Advanz) - Concurrences

UK Competition Authority The England & Wales Court of Appeal upholds the Competition Authority’s £99M fine for charging the NHS excessively high prices for a...

March 12 Pharmaceutical Technology

Advanz Pharma Closes Acquisition of Correvio Pharma | Pharmaceutical Technology

Global pharmaceutical company, Advanz Pharma, has closed its acquisition of specialty pharmaceutical company, Correvio Pharma.

January 14 Pharmaceutical Technology

Nordic Capital Acquires Advanz Pharma for $846 Million | Pharmaceutical Technology

The acquisition of Advanz Pharma by Nordic Capital has now completed, in a deal worth $846 million.

Never miss news about Advanz Pharma

Track Advanz Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Advanz Pharma competitors & trending companies

Browse news for competitors to Advanz Pharma and other trending companies.